Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [5631]

ESMO 2025: DNA shed by colon cancers may help personalise postsurgical treatment

ESMO 2025: DNA shed by colon cancers may help personalise postsurgical treatment

Precision reprogramming: How AI tricks cancer’s toughest cells

Precision reprogramming: How AI tricks cancer’s toughest cells

Combination therapy could expand treatment options for AML patients, extend survival

Combination therapy could expand treatment options for AML patients, extend survival

ESMO 2025: Research targets treatment resistance in neuroendocrine tumours

ESMO 2025: Research targets treatment resistance in neuroendocrine tumours

Disrupting cancer’s secret hubs: A new way to halt tumour growth

Disrupting cancer’s secret hubs: A new way to halt tumour growth

ESMO 2025: VT3989 continues to show promising early results in patients with advanced mesothelioma

ESMO 2025: VT3989 continues to show promising early results in patients with advanced mesothelioma

ESMO 2025: New generation of antibody-drug conjugates shows promise in early-stage disease

ESMO 2025: New generation of antibody-drug conjugates shows promise in early-stage disease

ESMO 2025: Trial results show belzutifan shrinks rare neuroendocrine tumours and improves symptoms

ESMO 2025: Trial results show belzutifan shrinks rare neuroendocrine tumours and improves symptoms

ESMO 2025: Dual targeted therapy shows promise in previously treated advanced kidney cancer

ESMO 2025: Dual targeted therapy shows promise in previously treated advanced kidney cancer

Study reveals how bacteria in tumours drive treatment resistance in cancer

Study reveals how bacteria in tumours drive treatment resistance in cancer

More from ecancer